TipRanks reveals the top 10 health care sector analysts of the past decade

TipRanks reveals the top 10 health care sector analysts of the past decade


A customer used an automated teller machine (ATM) at a Truist Bank branch in Dallas, Texas, US, on Friday, April 14, 2023.

Shelby Tauber | Bloomberg | Getty Images

The health care sector experienced rapid change over the past decade with the rise of digital services, bringing a range of opportunities to invest. 

TipRanks recognized Wall Street’s 10-best analysts in the space for identifying the best investment opportunities. These analysts outdid their peers with their stock picking and generated noteworthy returns through their recommendations.

TipRanks leveraged its Experts Center tool to recognize the ones with a high success rate. We also analyzed each stock recommendation made by health care sector analysts in the past decade. 

The ranking shows the analysts’ ability to deliver returns from their recommendations. TipRanks’ algorithms calculated the statistical significance of each rating, average return and the analysts’ overall success rate. In addition, every rating was measured over one year.

Top 10 analysts from the healthcare sector

The image shows the most successful Wall Street analysts from the healthcare sector, in descending order.

1. Thomas Smith – SVB Securities 

Thomas Smith tops the list. Smith has an overall success rate of 51%. His best rating has been on Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biopharma company focusing on therapies for metabolic and endocrine disorders. His buy call on VKTX stock from April 27, 2022 to April 27, 2023 generated a stellar return of 791.30%.

2. Brandon Couillard – Jefferies 

Brandon Couillard is second on this list and has a success rate of 68%. Couillard’s top recommendation is Exact Sciences (NASDAQ:EXAS), a provider of cancer screening and diagnostic tests. The analyst generated a profit of 450% through his buy recommendation on Exact Sciences stock from May 4, 2016 to May 4, 2017. 

3. David Windley – Jefferies 

Jefferies analyst David Windley ranks No. 3 on the list. Windley has a success rate of 68%. His best recommendation has been on Medidata Solutions, a tech-based company with clinical expertise. Dassault Systemes later acquired Medidata. The analyst generated a turn of 175.70% through a buy recommendation on MDSO from Aug. 01, 2012 to Aug. 01, 2013.

4. John Eade – Argus Research 

John Eade bags the fourth spot on the list. The five-star analyst has a 69% overall success rate. Eade’s best recommendation has been on Moderna (NASDAQ:MRNA), a pharmaceutical and biotechnology company. His buy call on MRNA stock generated a 265.90% return from June 30, 2020 to June 30, 2021.

5. Michael Wiederhorn – Oppenheimer

Fifth-place analyst Michael Wiederhorn has a success rate of 66%. His best recommendation is Community Health Systems (NYSE:CYH), a company engaged in the management and operations of hospitals. The analyst delivered a profit on this stock of 298.2% from May 1, 2020 to May 1, 2021.

6. Charles Duncan – Cantor Fitzgerald

Taking the sixth position is Charles Duncan. The analyst has a success rate of 52%. His top recommendation was Novavax (NASDAQ:NVAX), a biotech company that develops vaccines. Through his buy call on NVAX stock, Duncan generated a solid return of 800% from March 17, 2020 to March 17, 2021.

7. Yaron Werber – TD Cowen

TD Cowen analyst Yaron Werber is seventh on this list, with a success rate of 65%. Werber’s best call has been a buy on the shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharma company focusing on developing innovative medicines for rare and ultrarare diseases. The recommendation generated a return of 267.50% from Dec. 18, 2019 to Dec. 18, 2020.

8. Geulah Livshits – Chardan Capital

In the eighth position is Geulah Livshits of Chardan Capital. Livshits has an overall success rate of 42%. The analyst’s top recommendation is Cabaletta Bio (NASDAQ:CABA), a clinical-stage biotech company focused on developing therapies for autoimmune diseases. Based on her buy call on CABA, the analyst generated a profit of 800% from Oct. 11, 2022 through now. 

9. Richard Newitter – Truist Financial

Richard Newitter ranks ninth on the list. The five-star analyst sports a 62% success rate. His top recommendation has been on Organogenesis (NASDAQ:ORGO), a regenerative medicine company providing products for advanced wound care and surgical biologics. The buy recommendation generated a return of 397.9% from May 12, 2020 to May 12, 2021.

10. Boris Peaker – TD Cowen

Boris Peaker has the 10th spot on the list, with a success rate of 47%. Peaker’s best call has been a buy on shares of Trillium Therapeutics, a clinical-stage company developing therapies for cancer treatment. Pfizer (NYSE:PFE) later acquired Trillium. The recommendation generated a return of 800% from Jan. 7, 2020 to Jan. 7, 2021.

Bottom Line

Investors could follow the recommendations of top analysts to form a well-informed investment decision. You can also look at all the analysts who made it to the top 100 list. We will soon return with the top 10 analysts of the past 10 years from the Consumer Goods sector.

 



Source

Moody’s downgrades United States sovereign credit rating, citing growth in government debt
World

Moody’s downgrades United States sovereign credit rating, citing growth in government debt

Kent Nishimura | Los Angeles Times | Getty Images Moody’s Ratings cut the United States’ sovereign credit rating down a notch to Aa1 from the Aaa, the highest possible, citing the growing burden of financing the federal government’s budget deficit and the rising cost of rolling over existing debt amid high interest rates. “This one-notch […]

Read More
Leon Cooperman is still heavily invested in energy stocks and has a new MLP pick
World

Leon Cooperman is still heavily invested in energy stocks and has a new MLP pick

Leon Cooperman, Omega Family Office chair and CEO, remained heavily invested in energy stocks at the end of the first quarter, while adding a new master limited partnership. The billionaire investor took a small stake worth $16.5 million in Sunoco LP last quarter, according to a new regulatory filing. The fuel distributor is up about 9% […]

Read More
Wait and see: Ned Davis won’t go all in on stocks until the impact of tariffs is seen
World

Wait and see: Ned Davis won’t go all in on stocks until the impact of tariffs is seen

Many investors are breathing a sigh of relief that stocks seem to be making a comeback. Ned Davis Research says: not so fast. President Donald Trump’s trade policies wreaked havoc on markets to start the year, dragging down the S & P 500 18.9% between its all-time high in February and its closing low in […]

Read More